COSMIC: Chemotherapy plus Ofatumumab at Standard or Mega dose In CLL

Registry ID

EUCTR2011-000796-14

Source registry

EUCTR

Status

GB - no longer in EU/EEA

Phase

PHASE2

Sponsor

Leeds Teaching Hospitals NHS Trust

Start date

2011-12-01

Last update

2026-08-16

Conditions

• Chronic Lymphocytic Leukaemia (CLL)

Summary

This trial is intended to assess the efficacy of two doses of Ofatumumab (standard dose or high dose) in combination with chemotherapy (Fludarabine and Cyclophosphamide or Bendamustine) in relapsed B-CLL patients. The efficacy will be assessed by the complete response rates (CR or CR(i) by IWCLL criteria) in each treatment group.

Locations

• , , UK

Related clinical trials

• Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.
• Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project

View on source registry